Recent clinical evidence demonstrates that transcranial radiofrequency wave treatment increases VEGF levels in Alzheimer’s disease patients, correlating with enhanced clearance of tau and amyloid-β proteins from the brain through facilitation of meningeal lymphatic vessel flow and toxin clearance [40]. The gene discussed is VEGFA; the disease is early-onset autosomal dominant Alzheimer disease.